Single Source: Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Data Processing, Analysis, and Coordination Center (DPACC) (U24 Clinical Trial Not Allowed)
Grant Opportunity Analysis
The National Institute of Mental Health is issuing a single-source cooperative agreement to Brigham and Women’s Hospital to continue the Accelerating Medicines Partnership® Schizophrenia Data Processing, Analysis, and Coordination Center. The work will support processing and analysis of longitudinal, multi-modal biomarker and clinical outcome data collected across the AMP SCZ effort, including data from more than 2,600 participants. The project is intended to complete analysis of 24 months of data and uses a U24 mechanism with no clinical trial allowed; the project period is a maximum of three years. Only Brigham and Women’s Hospital is eligible to apply, applications are due June 9, 2026, and the intended funding is $5,000,000 for one award.
Eligible Applicants
Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Eligible Organizations:Only the Brigham and Women's Hospital may apply for this single source NOFO.Only the following applicant is eligible to apply for this single source funding: Brigham and Women"s Hospital. Please refer to Section I. Notice of Funding Opportunity Information for more details.Foreign Organizations/Foreign Collaborations:Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.